Last reviewed · How we verify
Etoricoxib + Tizanidine fixed dose
Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while tizanidine acts as a central alpha-2 adrenergic agonist to relieve muscle tension.
Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while tizanidine acts as a central alpha-2 adrenergic agonist to relieve muscle tension. Used for Acute musculoskeletal pain with muscle spasm, Chronic pain conditions with associated muscle tension.
At a glance
| Generic name | Etoricoxib + Tizanidine fixed dose |
|---|---|
| Also known as | Etori + Tiza |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | COX-2 selective inhibitor + centrally-acting muscle relaxant |
| Target | COX-2 enzyme; alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Musculoskeletal Disorders |
| Phase | Phase 3 |
Mechanism of action
This fixed-dose combination targets pain and muscle spasticity through dual mechanisms: etoricoxib blocks cyclooxygenase-2 (COX-2), reducing prostaglandin-mediated inflammation and pain signaling, while tizanidine activates alpha-2 adrenergic receptors in the spinal cord and brainstem to suppress motor neuron activity and reduce muscle tone. Together, they provide complementary analgesic and muscle-relaxant effects for musculoskeletal conditions.
Approved indications
- Acute musculoskeletal pain with muscle spasm
- Chronic pain conditions with associated muscle tension
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Gastrointestinal upset
- Headache
Key clinical trials
- Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm (PHASE3)
- Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: